Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies and Companion Diagnostics 2014

Michael Heller's Biography



Michael Heller, Distinguished Scientist - Knight Cancer Institute at Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR); Professor, University of California-San Diego

Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. From 1976 to 1984 he was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) During that time he carried out early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production, and he developed some of the first fluorescent resonant energy transfer (FRET) and chemiluminescent oligonucleotide probes for DNA hybridization analysis. He also oversaw Amoco’s sponsored energy and chemical research work at Cetus Corporation, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987. He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989. He was a co-found of Nanogen, and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for clinical diagnostic genotyping applications. Dr. Heller is a Professor (Recall/Emeritus) in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He is also now a Distinguished Scientist at the Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR), in Portland, Oregon. He has recently co-founded a new company called Biological Dynamics which is developing new sample to answer cancer diagnostics technology, based on the novel dielectrophoretic (DEP) technology developed at his UCSD lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology, with particular expertise in the areas of DNA probe diagnostics, DC and AC electrokinetic devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanocomponents. Dr. Heller has a respectable publication record, and has been an invited speaker to a large number of scientific conferences, which now include recent meetings on cell free nucleic acid and exosome biomarkers for cancer detection and molecular diagnostics. He also has over 55 issued US patents in the molecular diagnostics, biotechnology and nanotechnology areas.

Michael Heller Image

Rapid Isolation and Detection of DNA/RNA Biomarkers from Blood and Plasma “Key to Liquid Biopsy Diagnostics”

Monday, 27 October 2014 at 16:45

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

The analysis of circulating cell free (ccf) DNA and RNA continues to become more widely used for cancer diagnostics and management. The parallel development of new methods that allow rapid isolation directly from small amounts of blood or plasma will also be necessary to advance liquid biopsy point of care (POC) diagnostic applications. We have now demonstrated a dielectrophoretic (DEP) based approach that allows cfc-DNA and RNA biomarkers from chronic lymphocytic leukemia (CLL) patients to be isolated in about 10 minutes directly from a small volume (25ul) of patient whole blood or plasma.


Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid Biopsies and Companion Diagnostics 2014Biofluid Biopsies and Companion Diagnostics 2014 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com